|
Disease-free interval
|
|
Bcl-2 expression
|
Bcl-2+ versus Bcl-2–
|
0.017
|
0.09
|
0.01–0.64
|
|
Pathologic tumor size
|
pT ≥ 20 mm versus < 20 mm
|
0.047
|
2.23
|
1.02–4.91
|
|
Tumor-associated inflammation
|
Absence to mild versus moderate to severe
|
0.033
|
0.40
|
0.18–0.92
|
|
Overall survival
|
|
Bcl-2 expression
|
Bcl-2+ versus Bcl-2–
|
0.008
|
0.28
|
0.11–0.72
|
|
Pathologic tumor size
|
pT ≥ 20 mm versus < 20 mm
|
0.014
|
2.07
|
1.16–3.70
|
|
Tumor-associated inflammation
|
Absence to mild versus moderate to severe
|
0.012
|
0.44
|
0.23–0.84
|
|
Cancer-specific survival
|
|
Bcl-2 expression
|
Bcl-2+ versus Bcl-2–
|
0.031
|
0.31
|
0.11–0.89
|
|
Pathologic tumor size
|
pT ≥ 20 mm versus < 20 mm
|
0.026
|
2.10
|
1.09–4.02
|
|
Tumor-associated inflammation
|
Absence to mild versus moderate to severe
|
0.022
|
0.43
|
0.21–0.88
|
